Molecular Templates, Inc. Announces Pricing of $75.9 Million Public Equity Offering
February 18, 2021 07:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Announces Proposed Public Offering of Common Stock
February 17, 2021 16:05 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for the Discovery and Development of Next Generation Engineered Toxin Bodies for the Treatment of Cancer
February 11, 2021 07:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM; “Molecular Templates” or “MTEM”) today announced that it has entered into a worldwide strategic research...
Molecular Templates Announces FDA Acceptance of IND Application for MT-6402, a PD-L1-Targeted Engineered Toxin Body Enabled with Proprietary Antigen Seeding Technology
January 19, 2021 08:00 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the...
Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study
December 21, 2020 16:30 ET
|
Molecular Templates, Inc.
Phase 1 Study Dose Escalation Ongoing in All HER2 Positive Tumor Types HER2 Positive Breast Cancer Expansion Cohort Planned to be Initiated in 1H21 Expansion Cohorts in Additional Tumors Types to...
Molecular Templates to Participate in Upcoming Virtual Investor Conferences
November 16, 2020 16:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
November 05, 2020 16:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the...
Molecular Templates to Participate in September Virtual Investor Conferences
September 03, 2020 08:00 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Reports Second Quarter 2020 Financial Results
August 06, 2020 16:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the...
Molecular Templates, Inc. Raises $43 Million in Gross Proceeds Through Its At-the-Market Facility
July 20, 2020 16:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, July 20, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the...